skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Synthetic heparin-binding growth factor analogs

Patent ·
OSTI ID:1176079
; ; ;

The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain that binds a heparin-binding growth factor receptor, covalently bound to a hydrophobic linker, which is in turn covalently bound to a non-signaling peptide that includes a heparin-binding domain. The synthetic heparin-binding growth factor analogs are useful as soluble biologics or as surface coatings for medical devices.

Research Organization:
Brookhaven National Laboratory (BNL), Upton, NY (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC02-98CH10886
Assignee:
BioSurface Engineering Technologies, Inc. (Rockville, MD); Brookhaven National Laboratory (Upton, NY)
Patent Number(s):
7,166,574
Application Number:
10/224,268
OSTI ID:
1176079
Resource Relation:
Patent File Date: 2002 Aug 20
Country of Publication:
United States
Language:
English

References (19)

Engineering of an FGF–proteoglycan fusion protein with heparin-independent, mitogenic activity journal June 2000
Role of heparan sulfate in fibroblast growth factor signalling: a structural view journal September 2001
A heparin binding synthetic peptide from human HIP / RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin journal February 2003
Tandem Ligation of Multipartite Peptides with Cell-Permeable Activity journal January 2003
Semirational design of a potent, artificial agonist of fibroblast growth factor receptors
  • Ballinger, Marcus D.; Shyamala, Venkatakrishna; Forrest, Louise D.
  • Nature Biotechnology, Vol. 17, Issue 12, p. 1199-1204 https://doi.org/10.1038/70746
journal December 1999
A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein journal June 1998
Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice journal July 2001
Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans journal March 2000
Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts journal August 1997
Growing better blood vessels journal November 2001
Polymeric system for dual growth factor delivery journal November 2001
Directly Linked Soluble il-6 Receptor–Il-6 Fusion Protein Induces Astrocyte Differentiation from Neuroepithelial Cells via Activation of Stat3 journal March 2001
αvβ3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells journal December 1997
Synthesis of Native Proteins by Chemical Ligation journal June 2000
A Recombinant Human TGF-β1 Fusion Protein with Collagen-Binding Domain Promotes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells journal August 1999
Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. journal January 1991
A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells journal June 1997
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis journal April 2000
MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1 journal March 1999

Similar Records

Related Subjects

59 BASIC BIOLOGICAL SCIENCES